Skip to content
About LineaRx
Leadership Team
Investor Info
Linea DNA Platform
Applications
News
Events
Resources
Let’s Connect
About
About LineaRx
Leadership Team
Investor Info
Platform
Applications
News
Events
Resources
Let’s Connect
LineaRx Publishes Manuscript Demonstrating that a LinearDNA™ Vaccine Candidate was Protective in Virus Challenge Trial in Ferrets
September 30, 2022
Read More
email
APDN, Evvivax Announce LinearDNA™ Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines
May 6, 2021
Read More
email
Recent Press Releases
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-cell Therapy Produced from LineaDNA
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit
Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
Applied DNA and Alphazyme Conclude Linea™ RNAP Manufacturing Scale-Up Project, Deliver Substantial Improvement in Linea™ IVT Platform Economics
Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea™ IVT Platform
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA’s Linea DNA™ for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program
Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea™ RNAP, Progresses Towards GMP Linea™ IVT Production Start
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
